SIRLNT

Across TCGA pan-cancer cohorts, SIRLNT RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated SIRLNT data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SIRLNT RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SIRLNT expression acts as an unfavorable survival marker, although some lineages such as CESC and BRCA show a favorable association.

LIHC, DLBC, and KIRC are the cancer types where SIRLNT RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.509	0.711	<.001	81	view →
DLBC	OS	Tertile	IV	0.338	1.000	.001	76	view →
KIRC	DFS	Quartile	III,IV	0.462	0.696	.002	74	view →
KICH	DFS	Tertile	III,IV	0.053	0.789	<.001	73	view →
MESO	OS	Tertile	II,III,IV	0.350	0.617	<.001	72	view →
HNSC	OS	Tertile	All	0.523	0.735	.002	54	view →
LUAD	OS	Tertile	III,IV	0.525	0.714	.006	54	view →
UCS	OS	Tertile	IV	0.294	0.664	.012	36	view →
UCEC	OS	Tertile	All	0.865	0.936	.002	30	view →
TGCT	DFS	Median	II,III,IV	0.697	0.996	.017	18	view →
PCPG	DFS	Tertile	All	0.728	0.907	.007	18	view →
SKCM	DFS	Tertile	III,IV	0.356	0.629	.003	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

SIRLNT–LIHC (OS)

Open the LIHC breakdown →